Insider · CIK 0001604457
Neal Walker
ceopresidentofficerdirector
Files at ALDX (Aldeyra Therapeutics, Inc.), ACRS (Aclaris Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +62,728 | $0.00 | $0 | 62,728 | Jun 12, 2025 |
| Jun 10, 2025 | ALDX Aldeyra Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +2,413 | $0.00 | $0 | 2,413 | Jun 12, 2025 |
| May 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,467 | - | - | 1,482,799 | May 5, 2025 |
| May 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -2,975 | $1.38 | $4,106 | 1,479,824 | May 5, 2025 |
| May 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 0 | May 5, 2025 |
| Apr 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,467 | - | - | 1,476,374 | Apr 3, 2025 |
| Apr 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -3,042 | $1.48 | $4,502 | 1,473,332 | Apr 3, 2025 |
| Apr 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 9,467 | Apr 3, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,466 | - | - | 1,470,184 | Mar 4, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -3,277 | $1.99 | $6,521 | 1,466,907 | Mar 4, 2025 |
| Mar 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,466 | $0.00 | $0 | 18,934 | Mar 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,467 | - | - | 1,464,277 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -3,559 | $2.48 | $8,826 | 1,460,718 | Feb 4, 2025 |
| Feb 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 28,400 | Feb 4, 2025 |
| Feb 3, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +253,900 | $0.00 | $0 | 253,900 | Feb 4, 2025 |
| Feb 3, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +888,800 | $0.00 | $0 | 888,800 | Feb 4, 2025 |
| Jan 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,467 | - | - | 1,443,097 | Jan 3, 2025 |
| Jan 1, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -3,904 | $2.48 | $9,682 | 1,439,193 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +29,149 | - | - | 1,468,342 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -13,532 | $2.48 | $34k | 1,454,810 | Jan 3, 2025 |
| Jan 1, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 37,867 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +88,333 | $0.00 | $0 | 88,333 | Jan 3, 2025 |
| Jan 2, 2025 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -29,149 | $0.00 | $0 | 59,184 | Jan 3, 2025 |
| Dec 4, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +118,840 | $1.52 | $181k | 1,501,973 | Dec 6, 2024 |
| Dec 4, 2024 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -68,343 | $3.76 | $257k | 1,433,630 | Dec 6, 2024 |
| Dec 4, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -118,840 | $0.00 | $0 | 0 | Dec 6, 2024 |
| Dec 1, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,466 | - | - | 1,385,854 | Dec 3, 2024 |
| Dec 1, 2024 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -2,721 | $4.07 | $11k | 1,383,133 | Dec 3, 2024 |
| Dec 1, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,466 | $0.00 | $0 | 47,334 | Dec 3, 2024 |
| Nov 1, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Common Stock | +9,467 | - | - | 1,379,109 | Nov 5, 2024 |
| Nov 1, 2024 | ACRS Aclaris Therapeutics, Inc. | FTax withholding Common Stock | -2,721 | $2.09 | $5,687 | 1,376,388 | Nov 5, 2024 |
| Nov 1, 2024 | ACRS Aclaris Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 56,800 | Nov 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.